The direct-to-consumer telehealth company said the workforce reduction is unrelated to its weight-loss drug sector.

CHICAGO, June 1 (Reuters) - A Gilead Sciences-backed therapy made with a patient's own white blood cells shrank tumors in 62% of patients with recurrent glioblastoma, a rare event for a fatal ...

Hims & Hers is evolving beyond its original focus, aggressively expanding into peptides and GLP-1, positioning itself as a leader in the biohacking and longevity markets. The company’s strategic ...

Hims & Hers Health (NYSE:HIMS) is laying off about 4% of its employees as the telehealth firm adapts its strategy in a market where the sale of cheaper compounded versions of popular weight loss ...

(Photo by: Michael Siluk/UCG/Universal Images Group via Getty Images) Hims & Hers Health (NYSE: HIMS), a telehealth platform, experienced an 8% increase in its stock on Friday, May 30th ...

This is bringing a new class of tech-driven innovators to the forefront. Hims & Hers Health, Inc. HIMS and American Well Corporation AMWL, popularly known as Amwell, stand out as emerging players ...

Hims & Hers Health Inc. is cutting more than 4% of its workforce as it pivots away from selling cheap copycat versions of popular weight-loss drugs. The San Francisco-based telehealth company employs ...

NEW YORK, May 30 (Reuters) - Telehealth platform Hims & Hers (HIMS.N), opens new tab will cut 68 employees, or about 4% of its workforce, as it adjusts to a U.S. ban on manufacturing mass copies ...

If you’re on the fence about investing in UnitedHealth Group Incorporated, Hims & Hers Health or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors ...

Hims & Hers currently has a market capitalization of $11.94 billion. It has an earnings yield of 1.4%, favorable than the industry’s negative yield. In the last reported quarter, HIMS delivered ...